Key Summary Points {#FPar1}
==================

Therapeutic inertia, or the failure to initiate or intensify treatment in a timely manner, is common in patients with type 2 diabetes and makes a substantial contribution to the burden associated with the disease in the USA.We performed a health economic modeling analysis to quantify the clinical and economic burden associated with poor glycemic control due to therapeutic inertia based on published clinical data and unit costs to estimate complication costs and lost workplace productivity.It was estimated that in a population of 13.4 million patients with poor glycemic control (HbA1c 9.0% \[75 mmol/mol\]), delaying intensification of therapy by 1 year was associated with a loss of approximately 13,390 life-years and increased total costs of USD 7.3 billion (1-year time horizon).This modeling analysis provides evidence that initiatives and interventions aimed at preventing therapeutic inertia could play an important role in improving clinical outcomes and avoiding excess costs.

Introduction {#Sec1}
============

Recently published figures from the Centers for Disease Control and Prevention (CDC) estimate that in the USA there are currently over 30 million people living with diabetes, of whom 90--95% have type 2 diabetes \[[@CR1]\]. Moreover, with over 4000 new diabetes cases diagnosed every day \[[@CR1]\], by 2030 the number of people living with diabetes is expected to reach approximately 55 million \[[@CR2]\]. Type 2 diabetes is a chronic progressive disease associated with cardiovascular, ophthalmic, and renal complications, which places a considerable, and growing, clinical and economic burden on often already overstretched healthcare systems. In the USA, over the period 2012--2017, the total economic burden associated with diabetes increased by 26% to US dollars (USD) 327 billion, of which USD 237 million was attributable to direct medical costs \[[@CR3]\]. The economic burden of diabetes is now such that the treatment and management of diabetes and its associated complications account for one in every four healthcare dollars spent in the USA \[[@CR3]\]. Any new interventions or initiatives with the potential to mitigate the burden of disease associated with diabetes may have a notable impact on overall healthcare spending in the USA.

A fundamental goal of type 2 diabetes therapy is to delay or ideally prevent long-term diabetes-related complications, which is achieved through an individualized approach to treatment including the maintenance of good glycemic control and management of other risk factors such as systolic blood pressure and serum lipid levels \[[@CR4]\]. Despite the elevated risk of diabetes-related complications associated with poor glycemic control, there is often a therapeutic inertia toward the intensification of treatment at all stages of disease. Data from the National Health and Nutrition Examination Survey (NHANES) indicated that, during 2011--2014, over one-third of patients failed to achieve individualized glycated hemoglobin (HbA1c) targets and 15.5% of patients had HbA1c \> 9.0% (75 mmol/mol) \[[@CR5]\]. A recent study reported that there was frequently a delay in physicians responding to poor glycemic control and that, even among patients with HbA1c ≥ 9.0% (75 mmol/mol), therapy was not intensified in more than 40% of patients during a 6-month follow-up period \[[@CR6]\]. Therapeutic inertia specifically around the time of initiation and intensification of insulin is especially pronounced, particularly in primary care \[[@CR7]\]. For example, in the USA, a recent real-world data analysis showed that even after eventually initiating basal insulin, at 6 months post-insulin initiation, 81% of patients failed to achieve a target of HbA1c \< 7.0% (53 mmol/mol) and at 12 months, only 67% of patients with HbA1c \> 9.0% (75 mmol/mol) had intensified treatment \[[@CR8]\]. These findings prompted the study authors to describe basal insulin uptitration in this study cohort as "slow and insufficient".

In light of recent reports highlighting the challenge of therapeutic inertia in the USA \[[@CR6], [@CR8]\], the aim of the present analysis was to examine the clinical and economic burden associated with poor glycemic control due to delayed intensification of therapy across a range of glycemic control scenarios and time horizons in the US setting on a patient and population level.

Methods {#Sec2}
=======

Modeling Approach {#Sec3}
-----------------

Long-term cost-effectiveness analysis was performed using the IQVIA CORE Diabetes Model (CDM) Version 9.0 (IQVIA, Basel, Switzerland). The CDM is a published and validated, non-product-specific policy analysis tool that can be used to project long-term clinical and economic outcomes in type 1 or type 2 diabetes \[[@CR9]--[@CR11]\]. Complications and mortality attributable to diabetes-related complications were captured with the risk for cardiovascular complications predicted using the United Kingdom Prospective Diabetes Study 68 equations and background mortality was included using US-specific life tables published by the World Health Organization \[[@CR12], [@CR13]\]. All simulations were performed using a first-order Monte Carlo approach.

Outcomes were projected over time horizons of 1, 2, 3, 5, 10, and 30 years and scenarios were assessed in which baseline HbA1c was set at 7.0% (53 mmol/mol), 9.0% (75 mmol/mol), 11.0% (97 mmol/mol), 13.0% (119 mmol/mol), and 15.0% (140 mmol/mol) (Table [1](#Tab1){ref-type="table"}) (a range of treatment effects were modeled for each baseline HbA1c value with targets set to 6.5% (48 mmol/mol), 7.0% (53 mmol/mol), 8.0% (64 mmol/mol), or 9.0% (75 mmol/mol) depending on baseline HbA1c). Glycemic control (HbA1c) targets were aligned with previously published guidance from the American Association of Clinical Endocrinologists for 6.5% (48 mmol/mol) and the American Diabetes Association (ADA) for 6.5% (48 mmol/mol), 7.0% (53 mmol/mol), and 8.0% (64 mmol/mol) according to individual patient characteristics \[[@CR14], [@CR15]\]. The HbA1c target of 9.0% is aligned with the US Healthcare Effectiveness Data and Information Set threshold for poor glycemic control \[[@CR16]\]. For each time horizon and baseline HbA1c, scenarios were performed comparing outcomes with immediate intensification of treatment versus a delay in intensification of 1, 2, 3, 5, and 7 years. In the analysis, simulated patients were assumed to maintain good glycemic control (at the specified target HbA1c level), or to be in poor glycemic control (at the baseline HbA1c level) for a defined period of time before HbA1c was lowered to the target level for the remaining duration of the simulation (or the patient died in the simulation). Only scenarios in which baseline HbA1c was set at 9.0% (75 mmol/mol) or 11.0% (97 mmol/mol) and target HbA1c was set at 7.0% (53 mmol/mol) are presented here; results for all other scenarios and additional information on HbA1c progression are reported in the Supplementary Material. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.Table 1Summary of modeled scenarios according to baseline HbA1c, target HbA1c, delay in intensification, and time horizonBaseline HbA1c,  % (mmol/mol)Target HbA1c,  % (mmol/mol)Immediate intensification versusTime horizon^a^7.0 (53)6.5 (48)1-year delay2-year delay3-year delay5-year delay7-year delay1 year2 years3 years5 years10 years30 years**9.0 (75)**8.0 (64)**7.0 (53)**6.5 (48)**1-year delay2-year delay3-year delay5-year delay7-year delay1** **year2** **years3** **years5** **years10** **years30** **years11.0 (97)**9.0 (75)8.0 (64)**7.0 (53)**6.5 (48)**1-year delay2-year delay3-year delay5-year delay7-year delay1** **year2** **years3** **years5** **years10** **years30** **years**13.0 (119)9.0 (75)8.0 (64)7.0 (53)6.5 (48)1-year delay2-year delay3-year delay5-year delay7-year delay1 year2 years3 years5 years10 years30 years15.0 (140)9.0 (75)8.0 (64)7.0 (53)6.5 (48)1-year delay2-year delay3-year delay5-year delay7-year delay1 year2 years3 years5 years10 years30 yearsModeled scenarios presented in the manuscript are in bold. See Supplementary Material for results for modeled scenarios not presented in the main text*HbA1c* glycated hemoglobin^a^Only simulations with time horizons equal to or longer than the delay of intensification were run

Cohort Characteristics {#Sec4}
----------------------

Baseline cohort characteristics were primarily sourced from a US-based population of patients newly diagnosed with type 2 diabetes published by Hillier and Pedula \[[@CR17]\] (Table [2](#Tab2){ref-type="table"}) supplemented where necessary with data from other published sources (see Supplementary Material) \[[@CR18]--[@CR20]\]. The mean (standard deviation) age of the simulated patient cohort was 53.0 (10.6) years and mean duration of disease was assumed to be 0 (0) years as patients were newly diagnosed. For parameters where baseline data were not available, CDM default values were used. Physiological risk factors other than HbA1c (e.g., lipid levels, systolic blood pressure) were assumed to remain constant over time to enable the comparison of different HbA1c targets and baseline levels.Table 2Baseline cohort characteristicsCharacteristicMean (SD)Age, years53.0 (10.6)Duration of diabetes, years0 (0)HbA1c,  %^a^7.0/**9.0**/**11.0**/13.0/15.0SBP, mmHg135 (18.0)BMI, kg/m^2^33.0 (27.0)Smokers,  %19.0Male,  %56.0White,  %65.4*BMI* body mass index, *HbA1c* glycated hemoglobin, *SBP* systolic blood pressure, *SD* standard deviation^a^Values presented in bold correspond to scenarios presented in the manuscript (other scenarios are presented in the Supplementary Material)

Costs and Other Model Settings {#Sec5}
------------------------------

Direct costs for diabetes-related complications were derived from published sources and, where necessary, inflated to 2018 USD using the US consumer price index specific to medical care in US cities (see Supplementary Material for full details of complication costs) \[[@CR21]\]. The analysis was performed from the societal perspective (i.e., including both direct and indirect costs), and indirect costs associated with lost productivity were calculated using the human capital approach based on estimates of days off work due to complications published by Sørensen and Ploug \[[@CR22]\], combined with median salary estimates published by the Bureau of Labor Statistics \[[@CR23]\]. Acquisition costs associated with glucose-lowering therapy were not included in the analysis. Future costs and clinical outcomes were discounted at 3.0% per annum in line with recommendations for the US setting \[[@CR24]\].

Population-Level Burden {#Sec6}
-----------------------

The burden associated with poor glycemic control was estimated on a national level using a prevalence-based approach. The prevalent population of patients with type 2 diabetes was estimated on the basis of figures published by the CDC (30.3 million cases of diabetes in 2015) \[[@CR1]\], together with the assumption that 90% of the overall diabetes population have type 2 diabetes \[[@CR25]\]. Results from the NHANES indicate that only about 50% of American adults with diabetes are achieving HbA1c targets \< 7.0% (\< 53 mmol/mol), with data collected between 2011 and 2014 indicating that 50.9% of patients with type 2 diabetes reached this goal \[[@CR5], [@CR26]\]. For the estimation of population burden in all HbA1c scenarios in the present analysis, it was therefore assumed that 49.1% of patients in the overall type 2 diabetes cohort (i.e., 13,389,570 patients) had poor glycemic control (this was defined as HbA1c ≥ 7.0% \[53 mmol/mol\] in the NHANES analysis) and did not intensify therapy in the first year of treatment.

Results {#Sec7}
=======

Population-Level Burden {#Sec8}
-----------------------

Modeling projections showed that failure to intensify therapy in a timely manner had a substantial impact on the economic burden associated with type 2 diabetes (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Assuming a mean baseline HbA1c of 9.0% (75 mmol/mol) in the population, a 1-year delay in intensification could cost 13,390 years of life, increase the cost of diabetes-related complications by USD 1.8 billion, and add USD 5.6 billion to lost workplace productivity costs in just 1 year (Table [3](#Tab3){ref-type="table"}). This corresponded to a total economic burden of USD 7.3 billion. Increasing delays in intensification and longer time horizons were associated with increasingly higher estimates of additional clinical and economic burden. This was evidenced in the scenario assuming a 7-year delay in intensification and a time horizon of 30 years: almost 3 million life-years were projected to be lost in the type 2 diabetes population, the cost of diabetes-related complications was increased by approximately USD 82.6 billion, and the additional costs associated with lost workplace productivity were estimated at USD 140.7 billion, resulting in a total cost burden of USD 223.3 billion.Table 3Population-level burden: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 9.0% \[75 mol/mol\], target HbA1c of 7.0% \[53 mmol/mol\])Intensification delay, yearsTime horizon, years12351030Reduction in life expectancy with poor glycemic control, years 113,39026,77953,55880,337214,233642,699 2--26,77953,55893,727361,5181,178,282 3----66,948133,896388,2981,727,255 5------147,285535,5832,383,343 7--------642,6992,999,264Cost of diabetes-related complications, USD millions 11755301338485182970716,637 2--40945815850816,23331,260 3----679111,54021,74842,659 5------14,28531,06165,413 7--------37,24882,639Lost productivity costs, USD millions 15551908811,79516,49431,18134,554 2--13,04818,32727,24653,87961,339 3----22,41736,68268,70983,596 5------45,88997,257114,227 7--------115,701140,688Total costs, USD millions 1730612,10115,64221,67640,88851,192 2--17,14224,14335,75470,11292,599 3----29,20848,22290,457126,255 5------60,174128,318179,640 7--------152,949223,326*HbA1c* glycated hemoglobin, *USD* United States dollarsTable 4Population-level burden: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 11.0% \[97 mmol/mol\], target HbA1c of 7.0% \[53 mmol/mol\])Intensification delay, yearsTime horizon, years12351030Reduction in life expectancy with poor glycemic control, years 113,39066,948107,117187,454535,5831,713,865 2--66,948133,896254,402736,4262,664,524 3----133,896321,350923,8803,735,690 5------334,7391,312,1785,677,178 7--------1,579,9697,873,067Cost of diabetes-related complications, USD millions 143767358957413,60723,35643,963 2--10,11514,70322,15240,60877,828 3----17,36129,21155,038108,053 5------36,43679,259163,508 7--------96,279209,727Lost productivity costs, USD millions 114,32122,37629,58542,74078,24088,695 2--33,25146,03969,468127,959147,806 3----56,68190,186168,795197,665 5------111,878234,854277,021 7--------276,930338,445Total costs, USD millions 118,69729,73439,15856,347101,596132,658 2--43,36660,74291,619168,567225,633 3----74,042119,397223,833305,719 5------148,314314,113440,530 7--------373,210548,172*HbA1c* glycated hemoglobin, *USD* United States dollars

Assuming poorer glycemic control in the population at baseline (mean HbA1c 11.0% \[97 mmol/mol\]), model projections showed that delayed intensification of therapy was associated with an even greater economic burden (Table [4](#Tab4){ref-type="table"}). With the higher baseline HbA1c, a 1-year delay in intensification was projected to increase the costs associated with diabetes-related complications by USD 4.4 billion and lost productivity costs by USD 14.3 billion, resulting in a total cost of approximately USD 18.7 billion over the course of only 1 year. Modeling scenarios with longer time horizons and longer delays in intensification of therapy were associated with an even greater clinical and economic burden. In a population with a mean baseline HbA1c of 11.0% (97 mmol/mol), a 7-year delay in intensification was associated with a loss of 7,873,067 life-years over a 30-year time horizon. During this period, the time in poor glycemic control increased the cost of complications by approximately USD 209.7 billion and lost productivity costs went up by USD 338.4 billion, leading to a total increase in the economic burden of USD 548.2 billion.

Cost Savings per Patient {#Sec9}
------------------------

Consistent with the population level, patient-level results showed an increasing economic burden as delays in intensification lengthened and the time horizon increased (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). For patients with a baseline HbA1c of 9.0% (75 mmol/mol), a 1-year delay in intensification was associated with increased costs due to diabetes-related complications (USD 131) and lost productivity (USD 415), leading to an increase in total costs of USD 546 over a 1-year time horizon (Table [5](#Tab5){ref-type="table"}). Longer delays in intensification led to substantially greater cost increases. For example, assuming a 7-year delay and a 30-year time horizon, poor glycemic control was projected to increase complication costs by USD 6172 and lost productivity costs by USD 10,507, making a total of USD 16,679 per patient. In this scenario, poor glycemic control was associated with a reduction in life expectancy of approximately 0.22 years per patient due to the increased risk of diabetes-related complications.Table 5Patient-level outcomes: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 9.0% \[75 mol/mol\], target HbA1c of 7.0% \[53 mmol/mol\])Intensification delay, yearsTime horizon, years12351030Reduction in life expectancy with poor glycemic control, years 10.0010.0020.0040.010.020.05 2--0.0020.0040.010.030.09 3----0.010.010.030.13 5------0.010.040.18 7--------0.050.22Cost of diabetes related complications, USD 11312252873877251243 2--30643463512122335 3----50786216243186 5------106723204885 7--------27826172Lost productivity costs, USD 1415679881123223292581 2--9741369203540244581 3----1674274051326243 5------342772648531 7--------864110,507Total costs, USD 15469041168161930543823 2--12801803267052366916 3----2181360167569429 5------4494958313,416 7--------11,42316,679*HbA1c* glycated hemoglobin, *USD* United States dollarsTable 6Patient-level outcomes: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 11.0% \[97 mmol/mol\], target HbA1c of 7.0% \[53 mmol/mol\])Intensification delay, yearsTime horizon, years12351030Reduction in life expectancy with poor glycemic control, years 10.0050.010.010.010.040.13 2--0.010.010.020.060.20 3----0.010.020.070.28 5------0.030.100.42 7--------0.120.59Cost of diabetes-related complications, USD 1327550715101617443283 2--7551098165430335813 3----1297218241118070 5------2721591912,212 7--------719115,663Lost productivity costs, USD 1107016712210319258436624 2--248334385188955711,039 3----4233673612,60614,763 5------835617,54020,689 7--------20,68325,277Total costs, USD 1139622212925420875889908 2--32394537684312,58916,851 3----5530891716,71722,833 5------11,07723,46032,901 7--------27,87340,940*HbA1c* glycated hemoglobin, *USD* United States dollars

Patient-level burden was more pronounced in those with baseline HbA1c of 11.0% (97 mmol/mol). Projections showed that a 1-year delay in intensification increased total costs by approximately USD 1396 per patient over a 1-year time horizon, with approximately USD 327 of the total due to complication costs and USD 1070 due to lost productivity costs (Table [6](#Tab6){ref-type="table"}). The greatest increase in patient-level burden was observed with a 7-year delay in intensification and a 30-year time horizon. In this modeling scenario, poor glycemic control increased complication costs by USD 15,663 and lost productivity costs by USD 25,277, resulting in a total of USD 40,940 per patient. As well as substantially increased costs, life expectancy was reduced by 0.59 years per patient due to poor glycemic control in this scenario.

Discussion {#Sec10}
==========

Therapeutic inertia has been defined as a failure on the part of healthcare provider to initiate or intensify therapy when needed \[[@CR27]\] and has been shown to exist at all stages of the diabetes treatment paradigm, although therapeutic inertia toward the initiation of insulin is particularly pronounced \[[@CR6], [@CR28]--[@CR30]\]. This is one of the first analyses to provide US-specific quantitative estimates of the economic implications of delayed treatment intensification due to therapeutic inertia on both an individual patient and population level. Specifically, over a time horizon of just 1 year and assuming a baseline HbA1c of 9.0% (75 mmol/mol), a 1-year delay in treatment intensification was associated with an additional economic burden of USD 7.3 billion, including USD 1.8 billion due to diabetes-related complications. These population estimates are based on reports of the prevalent population of type 2 diabetes patients in 2017. In the USA, the absolute number of people living with type 2 diabetes is projected to almost double by 2030, meaning that the economic burden associated with delayed treatment intensification is likely to increase considerably over the next decade.

Alongside the economic burden, the clinical implications of delayed treatment intensification are also considerable. A 1-year delay in intensification from 9.0% to a target of 7.0% was projected to cost the population 642,699 years of life over a 30-year time horizon. The impact of poor glycemic control projected here is, on an individual patient level, aligned with data reported previously. For example, in a UK-based analysis, Paul et al. \[[@CR31]\] reported that for patients with HbA1c ≥ 7.0% (53 mmol/mol) (versus \< 7.0%) a 1-year delay in treatment intensification was associated with a 67% increase in the risk of myocardial infarction and a 51% increase in the risk of stroke. Similarly, a 2017 modeling analysis, conducted using the Archimedes model, also reported a higher incidence of complications with delayed intensification \[[@CR32]\].

In the present analysis, the consequences of intensification delays ranging from 1 to 7 years were explored, which is in line with those reported in routine clinical practice. In one UK-based analysis, the median time to intensification for patients on one, two, or three oral antidiabetes drugs (OADs) at baseline was 7.1, 6.1, and 6.0 years, respectively, and the mean HbA1c at the time of intensification was 8.7% (72 mmol/mol), 9.1% (76 mol/mol), and 9.7% (83 mmol/mol), respectively \[[@CR29]\]. In a second UK-based study, Khunti et al. \[[@CR30]\] reported that among insulin-treated patients with poor glycemic control (defined as HbA1c ≥ 7.5% \[58 mmol/mol\]) who did undergo treatment intensification, the median time to intensification was 3.7 years and mean HbA1c at intensification was \> 9.0% (75 mmol/mol). Additionally, it should be noted that the time frame of most clinical studies examining delays in intensification is such that, typically, only a short temporal window in the overall treatment paradigm is included in the analysis. As type 2 diabetes is a progressive disease, therapy has to be routinely intensified multiple times over a patient's lifetime to maintain good glycemic control and mitigate the risk of diabetes-related complications. There may well be intensification delays at each stage, meaning that the cumulative time spent in poor glycemic control may be longer than that reported in individual studies \[[@CR33]\]. The cumulative time spent with poor glycemic control was examined in a US-based analysis by Brown et al. \[[@CR34]\], who estimated that even in a well-controlled population, OAD-treated patients spent a mean time of almost 5 years with HbA1c \> 8.0% (64 mol/mol) prior to insulin initiation. Notably, this analysis was limited to patients treated with OADs and does not capture potential further cumulative time spent in poor glycemic control associated with any delays in intensification of therapy once patients initiated insulin.

The present analysis uses HbA1c targets that are aligned with previously published recommendations, e.g., the ADA targets of 6.5% (48 mmol/mol), 7.0% (53 mmol/mol), and 8.0% (64 mmol/mol) selected according to individual patient characteristics \[[@CR15]\]. In the most recent consensus report by the ADA and the European Association for the Study of Diabetes (EASD), the focus is on individual targets for each patient, stating that a "reasonable HbA1c target for most non-pregnant adults with sufficient life expectancy to see microvascular benefits (generally \~ 10 years) is around 53 mmol/mol (7%) or less", and noting that targets should be individualized on the basis of patient preferences, treatment goals, and the risk of adverse effects of therapy \[[@CR4]\]. While therapy targets are moving away from fixed HbA1c goals at the individual patient level, the use of such threshold values at a population level is still helpful in terms of understanding the benefits of new therapies in a given population, and for quantifying the burden of poor glycemic control. Moreover, the approach of using glycemic control thresholds for a population is aligned with previous publications on therapeutic inertia \[[@CR26], [@CR27], [@CR34]\].

Therapeutic inertia may arise at the patient, physician, or healthcare system level, or may be multifactorial emanating at a number of different levels. Barriers to treatment intensification at the patient level include a reluctance to initiate injectable therapies, poor health literacy, increased costs, unwillingness to undertake a more complex regimen, and fear of weight gain with insulin. At the physician level, fears over hypoglycemia have been documented specifically with regard to insulin initiation or intensification. Additionally, therapeutic inertia in relation to the initiation of insulin has been reported to be more common in primary care than for patients treated by secondary care specialists \[[@CR35]\]. Moreover, a number of studies have reported similar therapeutic inertia in patients receiving OADs, suggesting that therapeutic inertia can lead to poor glycemic control across the treatment continuum \[[@CR32]\]. Concern over increasingly complex regimens negatively influencing adherence has also been reported to contribute to therapeutic inertia at the physician level \[[@CR36], [@CR37]\]. The present analysis has shown that treatment delays of even 1 year, and the resultant time spent with poor glycemic control, are associated with substantial clinical and economic consequences. As such, initiatives aimed at overcoming therapeutic inertia both at the patient and physician level are likely to play an important role in combating the increasing burden of disease associated with type 2 diabetes. Initiatives that have been documented as helping overcome therapeutic inertia include patient education programs, simplifying treatment or titration regimens, and the inception of nurse practitioner-led diabetes care, with frequent follow-up allowing for the establishment of good patient--healthcare provider relationships and continuity of care as well as reassurance and assistance with issues such as timing and dosing of new therapies, management of treatment-related adverse events, and titration of insulin \[[@CR36]\]. In a recent review, Okemah et al. \[[@CR38]\] noted that therapeutic inertia results from healthcare provider-, patient-, and healthcare system-based factors, and represents a serious barrier to optimal treatment escalation and, as a result, glycemic control. The complex nature of inertia means that addressing it requires a combinatorial approach. The authors cited evidence supporting the role of patient education and involvement, personalizing therapy, patient feedback, education of healthcare providers and use of clinical decision support tools to reduce therapeutic inertia and improve outcomes for patients with type 2 diabetes.

The present study is associated with a number of limitations. Only costs associated with long-term diabetes-related complications were considered in the analysis. Costs associated with treatment (OADs and insulin) were not considered. Additionally, the clinical focus of the analysis was limited to HbA1c alone. Although there may be covariance between HbA1c and other physiological risk factors (such as lipid levels and systolic blood pressure) and management of these risk factors is an integral component of diabetes management, HbA1c was the only risk factor captured in the analysis. While this may present an overly simplistic picture of disease management, the rationale for this was that it permitted a focused analysis of HbA1c alone. The costs and quality of life deficits associated with hypoglycemic events were also not included in the current analysis. For patients with problematic hypoglycemic events, individualized HbA1c targets may be above the 7.0% (53 mmol/mol) threshold used here. The omission of hypoglycemic events should be noted when considering findings, particularly on an individual patient level. Allied to this, it should be noted that on an individual patient level, there are other circumstances in which physicians may tolerate poor glycemic control or set HbA1c target levels above 7.0% (53 mmol/mol); these may include instances where the patient has limited life expectancy or cases where multiple serious comorbid conditions are present.

Conclusion {#Sec11}
==========

The present health economic analysis has provided evidence that therapeutic inertia resulting in prolonged periods of time spent with poor glycemic control is likely to be associated with a substantial clinical and economic burden. Available clinical evidence has shown that achieving and maintaining good glycemic control is a crucial component of diabetes management in terms of delaying or preventing long-term diabetes-related complications. Initiatives that combat therapeutic inertia at the physician, patient, and health service level may help avert the clinical and economic consequences associated with unnecessary delays in intensification of treatment.
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